CA3198014A1 - Pharmaceutical composition for oral administration of edaravone and method of administering same - Google Patents
Pharmaceutical composition for oral administration of edaravone and method of administering sameInfo
- Publication number
- CA3198014A1 CA3198014A1 CA3198014A CA3198014A CA3198014A1 CA 3198014 A1 CA3198014 A1 CA 3198014A1 CA 3198014 A CA3198014 A CA 3198014A CA 3198014 A CA3198014 A CA 3198014A CA 3198014 A1 CA3198014 A1 CA 3198014A1
- Authority
- CA
- Canada
- Prior art keywords
- administration
- edaravone
- pharmaceutical composition
- meal
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020188514 | 2020-11-12 | ||
| JP2020-188514 | 2020-11-12 | ||
| PCT/JP2021/041673 WO2022102737A1 (ja) | 2020-11-12 | 2021-11-12 | エダラボン経口投与用医薬組成物およびその投与方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3198014A1 true CA3198014A1 (en) | 2022-05-19 |
Family
ID=81602356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3198014A Pending CA3198014A1 (en) | 2020-11-12 | 2021-11-12 | Pharmaceutical composition for oral administration of edaravone and method of administering same |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11911366B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4245303A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JPWO2022102737A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230098267A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116761601A (cg-RX-API-DMAC7.html) |
| AR (1) | AR124062A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021380319B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198014A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302533A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202228678A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022102737A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024036261A2 (en) * | 2022-08-10 | 2024-02-15 | Kpr U.S., Llc | Occlusion detection system and method for a flow control apparatus |
| EP4559463A1 (en) * | 2023-11-23 | 2025-05-28 | Ferrer Internacional, S.A. | Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61263917A (ja) | 1985-05-20 | 1986-11-21 | Mitsubishi Yuka Yakuhin Kk | 脳機能正常化剤 |
| JPH0531523A (ja) | 1991-07-26 | 1993-02-09 | Aichi Steel Works Ltd | ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置 |
| ES2248144T3 (es) | 2000-10-24 | 2006-03-16 | Mitsubishi Pharma Corporation | Medicamentos para tratar la esclerosis lateral amiotrofica (ela). |
| CN109125261B (zh) * | 2016-03-16 | 2021-11-30 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
| EP3785703A1 (en) * | 2017-01-17 | 2021-03-03 | Treeway TW001 B.V. | Treatment comprising oral or gastric administration of edaravone |
| CN110381923A (zh) * | 2017-01-17 | 2019-10-25 | 萃微Tw001公司 | 包括肠内施用依达拉奉的医学治疗 |
| BR112021008197A2 (pt) | 2018-11-02 | 2021-08-03 | Mitsubishi Tanabe Pharma Corporation | suspensão de edaravone para administração oral |
| JP7012792B2 (ja) | 2020-08-06 | 2022-01-28 | 株式会社 ディー・エヌ・エー | 動画を配信するためのシステム、方法、及びプログラム |
| US12194025B2 (en) | 2020-11-12 | 2025-01-14 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical composition for oral administration of edaravone and method of administering same |
-
2021
- 2021-11-12 JP JP2022562195A patent/JPWO2022102737A1/ja active Pending
- 2021-11-12 AR ARP210103147A patent/AR124062A1/es unknown
- 2021-11-12 AU AU2021380319A patent/AU2021380319B2/en active Active
- 2021-11-12 CN CN202180075839.XA patent/CN116761601A/zh active Pending
- 2021-11-12 EP EP21891982.7A patent/EP4245303A4/en active Pending
- 2021-11-12 CA CA3198014A patent/CA3198014A1/en active Pending
- 2021-11-12 TW TW110142253A patent/TW202228678A/zh unknown
- 2021-11-12 KR KR1020237017986A patent/KR20230098267A/ko not_active Ceased
- 2021-11-12 WO PCT/JP2021/041673 patent/WO2022102737A1/ja not_active Ceased
- 2021-11-12 IL IL302533A patent/IL302533A/en unknown
- 2021-12-29 US US17/564,538 patent/US11911366B2/en active Active
-
2023
- 2023-12-28 US US18/398,241 patent/US12478611B2/en active Active
-
2025
- 2025-01-07 JP JP2025002313A patent/JP2025061070A/ja active Pending
- 2025-05-22 AU AU2025203773A patent/AU2025203773A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12478611B2 (en) | 2025-11-25 |
| TW202228678A (zh) | 2022-08-01 |
| US20220142982A1 (en) | 2022-05-12 |
| JPWO2022102737A1 (cg-RX-API-DMAC7.html) | 2022-05-19 |
| AU2021380319B2 (en) | 2025-03-20 |
| IL302533A (en) | 2023-07-01 |
| US11911366B2 (en) | 2024-02-27 |
| CN116761601A (zh) | 2023-09-15 |
| AU2025203773A1 (en) | 2025-06-12 |
| WO2022102737A1 (ja) | 2022-05-19 |
| KR20230098267A (ko) | 2023-07-03 |
| US20240173297A1 (en) | 2024-05-30 |
| AR124062A1 (es) | 2023-02-08 |
| EP4245303A4 (en) | 2024-10-09 |
| EP4245303A1 (en) | 2023-09-20 |
| JP2025061070A (ja) | 2025-04-10 |
| AU2021380319A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2025203773A1 (en) | Pharmaceutical composition for oral administration of edaravone and method of administering same | |
| ES2774755T3 (es) | Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas | |
| US20160166543A1 (en) | Stable combination oral liquid formulation of melatonin and an antihistaminic agent | |
| US12310946B2 (en) | Pharmaceutical composition for oral administration of edaravone and method of administering same | |
| EP2754440B1 (en) | Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis | |
| US9132134B2 (en) | Methods for treating GI tract disorders | |
| US20150320712A1 (en) | Nutritional Composition for Gastrostomy-Tube Patients | |
| CN103989677A (zh) | 去亚甲基小檗碱在制备降血糖药物中的应用 | |
| Nisim et al. | Enteral nutrition support | |
| CN103919775A (zh) | 9-去甲基小檗碱在制备降血糖药物中的应用 | |
| CN109922801A (zh) | 甲硝唑和巴氯芬的混悬剂和稀释剂 | |
| JP6420797B2 (ja) | 活動意欲向上剤 | |
| TWI236907B (en) | An agent for improving hypoalbuminaemia | |
| BR112017027636B1 (pt) | Composições nutricionais líquidas ou semilíquidas e composições nutricionais | |
| EP4559463A1 (en) | Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders | |
| US12558347B2 (en) | Cevimeline liquid formulations | |
| JP6603450B2 (ja) | 高脂血症および/または脂肪肝の改善剤 | |
| JP2010265186A (ja) | 貧血予防用組成物 | |
| CN109223747A (zh) | 五加酸在制备抗抑郁症药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241002 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241002 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260428 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260512 |